GAMMA Investing’s Pacific Biosciences PACB Stock Holding History

GAMMA Investing’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.39K	Sell	585 -1,987	-77%	-$2.81K	﹤0.01%	4036
2026 Q2	$4.32K	Sell	2,572 -393	-13%	-$571	﹤0.01%	3530
2026 Q1	$3.91K	Sell	2,965 -8,568	-74%	-$15.3K	﹤0.01%	3455
2025 Q4	$21.6K	Buy	+11,533	New	+$22.2K	﹤0.01%	2568
2025 Q1	–	Sell	-305	Closed	-$558	–	3864
2024 Q4	$558	Buy	+305	New	+$595	﹤0.01%	3557
2024 Q2	–	Sell	-103	Closed	-$386	–	3496
2024 Q1	$386	Sell	103 -870	-89%	-$5.09K	﹤0.01%	3142
2023 Q4	$6.33K	Buy	+973	New	+$7.96K	﹤0.01%	2125

Other funds holding PACB

MCP

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

VVP

Venture Visionary Partners Sylvania, Ohio $3.82B AUM 21.33% 1-Year Est. Return

DWM

DKM Wealth Management Stockton, California $158M AUM 11.62% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's PACB Position: Q3 2026 in Review

GAMMA Investing reduced its Pacific Biosciences (PACB) stake by 77% in Q3 2026, selling an estimated $2.81K and leaving 585 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4036.

GAMMA Investing first reported a position in PACB in Q4 2023 and has held it in 7 quarters since. The position peaked at $21.6K in Q4 2025. 6 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

GAMMA Investing held 585 shares of Pacific Biosciences worth $1.39K as of Q3 2026.
GAMMA Investing sold 1,987 Pacific Biosciences shares in Q3 2026, an estimated $2.81K.
Pacific Biosciences made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4036 holding.
GAMMA Investing first reported a position in Pacific Biosciences in Q4 2023 and has held it in 7 quarters since.
GAMMA Investing's Pacific Biosciences position peaked at $21.6K in Q4 2025.
6 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.